GlycoMimetics's rivipansel nabs US Rare Pediatric status for sickle cell

• GlycoMimetics (NASDAQ:GLYC) jumps 17% after hours on FDA Rare Pediatric Disease tag for Rivipansel for the treatment of sickle cell disease.
• Rivipansel, a glycomimetic drug candidate that binds to all three members of the selectin family (E-, P- and L-selectin).
• In June, the company announced post hoc analysis of the failed Phase 3 RESET rivipansel trial for vaso-occlusive crisis in hospitalized sickle cell disease patients that showed a statistically significant improvement in the time readiness for discharge, the primary endpoint, in participants who received rivipansel within ~26 hours of the onset of pain.
• https://seekingalpha.com/news/3619966-glycomimeticss-rivipansel-nabs-us-rare-pediatric-status-for-sickle-cell